Company Number: 15052410

Analysis Date: 2025-07-29 19:25 UTC

1. Credit Opinion: CONDITIONAL APPROVAL
   Adnan Pharma Limited is a newly incorporated small private limited company operating in the dispensing chemist sector. With only one director and employee, and filing under the small companies exemption regime, it has limited operating history. The net asset position is positive but modest (£15,818) and the company holds sufficient cash (£25,962) to cover current liabilities (£10,144). However, the absence of historical profit & loss data and limited scale means credit exposure should be conservative and monitored closely. Approval is recommended with conditions including regular financial updates and limits on exposure until trading performance stabilizes.

2. Financial Strength:
   The balance sheet shows a small but positive net asset base, with shareholders’ funds of £15,818 primarily from retained earnings. The company has minimal fixed or long-term assets and relies on working capital and cash resources. The small share capital (£1) reflects typical structure for a start-up entity. Overall, the financial position is stable but fragile, typical for a micro business at an early stage with limited capitalization.

3. Cash Flow Assessment:
   Liquidity appears adequate with cash at bank of £25,962 exceeding current liabilities of £10,144, resulting in positive net current assets and working capital. This indicates the company can meet short-term obligations without immediate refinancing. However, cash flow sustainability depends on ongoing trading performance and receivables management, which is not detailed here. Early-stage companies often face cash flow volatility, so prudent cash monitoring is essential.

4. Monitoring Points:

• Track revenue growth and profitability trends once reported, to assess business viability and repayment capacity.
• Monitor cash flow statements regularly to ensure liquidity remains positive and working capital is managed efficiently.
• Watch for any increase in current liabilities or deterioration in net assets which could signal stress.
• Confirm that director remains active and no adverse regulatory or credit events occur.
• Review future filings for confirmation statement and accounts to detect changes in company structure or financial health.